Compare
Aquestive Therapeutics, Inc. vs Cumberland Pharmaceuticals Inc vs Xilio Therapeutics, Inc. vs Septerna, Inc.
| Latest fiscal year | Aquestive Therapeutics, Inc. AQST | Cumberland Pharmaceuticals Inc CPIX | Xilio Therapeutics, Inc. XLO | Septerna, Inc. SEPN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $44.55M | $44.52M | $43.77M | $45.95M |
| Revenue growth (YoY) | -22.6% | +17.6% | +589.9% | n/m |
| Gross margin | 58.3% (computed) | 85.0% (computed) | n/a | n/a |
| Operating margin | -159.5% | -6.3% | -95.9% | -148.6% |
| Net margin | -188.1% | -6.4% | -80.1% | -106.4% |
| Net income | -$83.78M | -$2.84M | -$35.04M | -$48.88M |
| EPS (Diluted) | -$0.78 | -$0.19 | -$4.19 | -$1.10 |
| Operating cash flow | -$52.43M | $4.93M | -$4.99M | $110.19M |
| Free cash flow | -$52.99M | $4.83M | -$5.51M | $109.67M |
| Cash & equivalents | n/a | $11.44M | $137.53M | $120.72M |
| Total assets | $160.43M | $76.82M | $154.69M | $596.19M |
| Total liabilities | $194.09M | $52.28M | $119.41M | $214.26M |
| Shareholders' equity | -$33.66M | $24.88M | $35.27M | $381.93M |
| Return on year-end equity | n/a | -11.4% | -99.3% | -12.8% |
| Shares outstanding | 122.04M | 14.96M | 4.53M | 44.81M |
Revenue, most recent five fiscal years
| Fiscal year | Aquestive Therapeutics, Inc. | Cumberland Pharmaceuticals Inc | Xilio Therapeutics, Inc. | Septerna, Inc. |
|---|---|---|---|---|
| Latest | $44.55M Ended 2025-12-31 | $44.52M Ended 2025-12-31 | $43.77M Ended 2025-12-31 | $45.95M Ended 2025-12-31 |
| 1 year earlier | $57.56M Ended 2024-12-31 | $37.87M Ended 2024-12-31 | $6.34M Ended 2024-12-31 | $1.07M Ended 2024-12-31 |
| 2 years earlier | $50.58M Ended 2023-12-31 | $39.55M Ended 2023-12-31 | n/a | $151.0K Ended 2023-12-31 |
| 3 years earlier | $47.68M Ended 2022-12-31 | $42.01M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $50.83M Ended 2021-12-31 | $35.05M Ended 2021-12-31 | n/a | n/a |